Peripheral Neuropathies
Polyneuropathy associated with anti-MAG IgM antibodies
Dec. 30, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Tumefactive demyelinating lesions …
- Updated 06.01.2024
- Released 06.25.2010
- Expires For CME 06.01.2027
Tumefactive demyelinating lesions
Introduction
Overview
When multiple sclerosis or its variants present with clinical and radiographic features of a brain tumor, this is referred to as tumefactive multiple sclerosis or tumefactive demyelinating lesions. Tumefactive demyelinating lesions often pose a diagnostic challenge. In this article, the authors discuss the spectrum of central nervous system inflammatory demyelinating disease that can have a tumefactive clinical or radiographic presentation, including Marburg acute multiple sclerosis, Balo concentric sclerosis, and Schilder disease. Tumefactive demyelinating lesions occurring in association with autoimmune diseases (eg, Sjogren disease, lupus erythematosus, neuromyelitis optica, MOG-antibody associated disease), infectious diseases (eg, HIV), malignancy (eg, renal cell carcinoma), related to drugs (eg, tacrolimus, fingolimod), and postinfectious conditions (eg, acute disseminated encephalomyelitis, acute hemorrhage leukoencephalitis) are not included. This updated review adds information from retrospective reviews, case series, and epidemiological studies.
Key points
|
• Tumefactive demyelinating lesions can be caused by a number of diseases, including multiple sclerosis. It is important to recognize that use of the terms tumefactive demyelinating lesions and tumefactive multiple sclerosis in the literature is not standardized and can cause confusion. | |
|
• A spectrum of disorders causes inflammatory demyelination of the central nervous system; the disorders are collectively referred to as CNS idiopathic inflammatory demyelinating diseases. | |
|
• Any type of CNS idiopathic inflammatory demyelinating disease may present clinically and radiographically as a tumefactive lesion. | |
|
• MRI features associated with tumefactive demyelination include multifocal lesions with at least a single dominant lesion larger than 2.0 cm, variable presence of mass effect or edema, and ring enhancement. | |
|
• Pathological features of tumefactive demyelinating lesions include focal demyelination, variable inflammation, gliosis, and relative axonal preservation. | |
|
• Two thirds of patients who present with tumefactive demyelinating lesions subsequently develop multiple sclerosis, with a relapsing-remitting disease course. | |
|
• High-dose intravenous corticosteroids are the first-line management for tumefactive relapses. | |
|
• Aggressive supportive management in the acute phase is crucial because the predicted long-term outcome of many patients is generally good. |
Historical note and terminology
Multiple sclerosis is a chronic CNS idiopathic inflammatory demyelinating disease characterized by multiple lesions disseminated in time and space. Multiple sclerosis is the most common CNS inflammatory demyelinating disease across all age groups. Typical multiple sclerosis lesions involve the white matter, with a predilection for the periventricular areas, cerebellum, brainstem, spinal cord, and optic nerves. Lesions typically range in size from a few millimeters to a centimeter in diameter (63). Multiple sclerosis is diagnosed on the basis of demonstrating multiple CNS lesions disseminated in time and space clinically or radiographically, with more recent updates including cerebrospinal fluid analysis (54; 67; 85). Occasionally, patients are found to have large CNS demyelinating lesions that appear tumor-like. These are known as tumefactive demyelinating lesions.
The terms tumefactive demyelinating lesions and tumefactive multiple sclerosis are often used interchangeably, although these terms are not synonymous. A tumefactive demyelinating lesion is any CNS demyelinating lesion that appears tumor-like. Tumefactive demyelinating lesions can be caused by a variety of disorders, including, but not limited to, multiple sclerosis. The term tumefactive multiple sclerosis usually refers to multiple sclerosis with tumor-like lesions, but this term is sometimes used to refer to both typical multiple sclerosis and the rare multiple sclerosis variants that can cause tumefactive lesions, including Marburg acute multiple sclerosis, Balo concentric sclerosis, and Schilder disease. Whether these entities are variants of multiple sclerosis, as they have historically been identified, or discrete pathophysiologic entities remains controversial. This article focuses on a workup of tumefactive demyelinating lesions and the variants of multiple sclerosis that present with tumefactive lesions:
|
• Marburg acute multiple sclerosis |
Tumefactive demyelination can also occur in other conditions including autoimmune diseases (eg, Sjogren disease, lupus erythematosus, neuromyelitis optica, associated with aquaporin 4 (AQP4) antibody, acute disseminated encephalomyelitis (ADEM), and myelin oligodendrocyte glycoprotein [MOG] antibody-associated disease), infectious diseases (eg, HIV), malignancy (eg, renal cell carcinoma), related to drugs (eg, fingolimod, tacrolimus), and postinfectious conditions (eg, acute disseminated encephalomyelitis, acute hemorrhage leukoencephalitis). These are beyond the scope of this article.
Tumefactive demyelinating lesions. Although this term is not used uniformly and consistently in the literature, it typically refers to demyelinating brain lesions 2 cm or larger in size, often with features of edema and mass effect. By MRI these can appear as a solitary large lesion or multiple lesions with variable contrast enhancement. These lesions may occur in prototypic multiple sclerosis, other causes of demyelination associated with infection, postinfection or autoimmune causes, or in the acute fulminant variants of CNS idiopathic inflammatory demyelinating diseases described below. In the largest study of patients with biopsy-proven tumefactive demyelinating lesions that included 168 patients (48), the majority (70%) were determined to have multiple sclerosis. When tumefactive lesions occur in prototypic multiple sclerosis, it is most often at initial presentation.
Disease-modifying therapy-associated tumefactive demyelination. There are growing numbers of reports of tumefactive demyelination in association with multiple sclerosis disease-modifying therapies, including alemtuzumab, natalizumab, and fingolimod. At least 20 cases of tumefactive demyelination associated with fingolimod have been reported (14; 33; 28; 65; 30; 86). These events have been reported to occur directly after drug initiation, 13 months into treatment (86), and shortly after discontinuation of fingolimod (71; 26). Although a causal link has not been proven, the association is striking. A few of these cases occurred in the setting of transitioning a patient from natalizumab to fingolimod (14; 33). There is one published case with biopsy of the tumefactive lesion, which showed typical pathologic changes associated with demyelination in multiple sclerosis (30). As has been reported by other authors—and we are in agreement—this likely represents a unique phenomenon and is not simply emergence of underlying highly active multiple sclerosis (30). Several disease-modifying therapies for multiple sclerosis, including interferon-beta and natalizumab, worsen neuromyelitis optica and cause tumefactive demyelinating lesions in patients with neuromyelitis optica (87). As tumefactive demyelination occurs more commonly as the first demyelinating event and tumefactive lesions have not been reported in association with glatiramer acetate, it is reasonable to hypothesize that an immunologic phenomenon occurring as a result of fingolimod treatment triggers these tumefactive lesions (30).
A single case of tumefactive demyelination associated with natalizumab has been reported in a patient with multiple sclerosis in the setting of discontinuation and early restarting of the medication (08). The patient in this case discontinued natalizumab, then had a relapse of multiple sclerosis without tumefactive lesions, prompting the providers to restart natalizumab. After restarting, she had a severe inflammatory relapse with tumefactive lesions. This case is notable because of the severity of the tumefactive disease activity, leading to stupor and quadriparesis. Biopsy of one of the tumefactive lesions showed demyelination and inflammation dominated by B cells. There are other reports of high-rebound disease activity without tumefactive lesions with discontinuation of natalizumab, but this may partially reflect more active disease in patients selected for treatment with natalizumab. The case presented by Beume and colleagues suggests the possibility of modification of the immune response by restarting natalizumab, leading to malignant disease activity (08).
A case of tumefactive demyelinating lesions has been reported 4 months after initiation of alemtuzumab for relapsing multiple sclerosis (06). Alemtuzumab is thought to prevent multiple sclerosis relapses by targeting CD52, causing rapid and prolonged depletion of lymphocytes. In the patient reported, there was early and disproportionate B-cell reconstitution with little increase in T-lymphocytes leading to dynamic alteration in T/B-lymphocyte ratio. Tumefactive demyelination has also been reported in a case of neuromyelitis optica after the third cycle of annual alemtuzumab infusions (04). Interferon beta can cause exacerbation of demyelination and tumefactive demyelinating lesions in neuromyelitis optica and within the first 6 to 12 months of therapy increases peripheral newly produced B-cells while decreasing T-lymphocytes (95).
One case of tumefactive demyelination has been reported with ocrelizumab in a patient with severe, fulminant disease who developed a tumefactive lesion prior to their third infusion (56). The patient’s pre-infusion CD19 was approximately 0.7%, suggesting only limited reconstitution of B cells. Whether that reconstitution was enough to lead to the exaggerated immune response is unclear. A brain biopsy was consistent with active demyelinating disease. A case of multiple severe tumefactive lesions with onset within 2 days of initiation of rituximab initiation has also been reported (55).
Marburg acute multiple sclerosis. This is an acute, fulminant, monophasic CNS idiopathic inflammatory demyelinating disease characterized by large hemispheric cerebral lesions and rapid progression to death within months to 1 year from onset. Marburg acute multiple sclerosis was first described by Otto Marburg in 1906. He described a 30-year-old woman presenting with confusion, headache, vomiting, ataxia, and left hemiparesis, rapidly progressing to death within 1 month. Autopsy revealed widespread destructive inflammatory demyelination. The clinical diagnosis of Marburg acute multiple sclerosis is often made in retrospect because it is difficult to predict the course and outcome at the onset of symptoms. Cases described in the literature typically show little or no response to treatment, including with high-dose corticosteroids, intravenous immunoglobulins, plasma exchange, azathioprine, cyclophosphamide, and mitoxantrone (88; 84; 81). There is one case report with a favorable response to high-dose cyclophosphamide (60). An additional patient eventually reached long-term disease stability, although with significant disability, after treatment with corticosteroids, cyclophosphamide, plasma exchange, and interferon-beta (88).
Balo concentric sclerosis. This acute CNS idiopathic inflammatory demyelinating disease is pathologically and radiographically characterized by a unique pattern of concentric demyelination. Josef Balo from Hungary first characterized the pathology of this disease in 1928 (05). Balo described a 23-year-old gentleman presenting with progressive right hemiparesis and numbness. Patients with Balo concentric sclerosis have traditionally been thought to have an acute fulminant presentation with rapid progression to death within 1 year, similar to Marburg acute multiple sclerosis; however, some people with Balo-like lesions detected on MRI have favorable outcomes (37; 29). In a review of 40 patients with Balo concentric sclerosis, approximately 10% died from their initial attack and half had a monophasic course (36). MRI is characterized by lesions with alternating concentric hyperintense and hypointense rings that may enhance with gadolinium (59). Lesions range in size from 1 centimeter to large sections of a cerebral hemisphere. Their distinctive appearance allows them to be distinguished from lesions in other CNS tumefactive disorders. The diagnosis of Balo concentric sclerosis is typically made based on MRI or autopsy findings demonstrating the pathologic hallmark of concentric demyelination.
Concentric CNS lesions can also rarely occur in other demyelinating disorders. Two case reports of patients with Balo-like brainstem lesions have been described. One patient had neuromyelitis optica (27), and the other had multiple sclerosis (40). Balo-like lesions have also been described in patients with progressive multifocal leukoencephalopathy (52), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (17), and a patient with active hepatitis C and CSF positive for human herpes virus 6 (25).
Schilder disease (myelinoclastic diffuse sclerosis). This very rare CNS idiopathic inflammatory demyelinating disease was initially described by Paul Schilder in 1912. It is a progressive, degenerative, demyelinating disorder of the CNS that usually begins in childhood or young adulthood (mostly males between the ages of 7 and 12). A number of patients initially diagnosed with Schilder disease were subsequently found to have other CNS disorders, including metabolic and hereditary leukodystrophies (eg, adrenoleukodystrophy = Addison-Schilder disease). As such, very long-chain fatty acid testing must be considered in the evaluation of suspected cases. Schilder disease typically causes large, bilateral, roughly symmetrical demyelinating lesions with progressive enlargement that ultimately interfere with motor function, speech, personality, hearing, and vision, and autonomic functions. In 1986, Poser and colleagues proposed criteria for this diagnosis (68). It may be difficult to distinguish Schilder disease from acute or subacute fulminant multiple sclerosis.
Clinical manifestations
Presentation and course
Because of their size, location, and potential for associated mass effect and edema, tumefactive demyelinating lesions cause neurologic symptoms atypical for multiple sclerosis. Among the largest cohort of biopsy-proven tumefactive demyelinating lesions analyzed to date (n=168), common presenting symptoms, in decreasing order of frequency included motor, cognitive, cerebellar, and brainstem dysfunction (48). Additional symptoms included headache, seizures, aphasia, cortical sensory loss, or psychosis. Unlike typical CNS demyelinating lesions, tumefactive lesions are more likely to cause cortical signs, such as altered mental status and visual field deficits. The tumefactive episode represented the initial event in 61% of cases; however, 29% of patients had a prior history of relapsing neurologic symptoms, and 5% carried an established diagnosis of multiple sclerosis.
Research suggests that two thirds of patients with tumefactive demyelinating lesions subsequently develop a relapsing-remitting disease course with more typical multiple sclerosis lesions, although a small subset will have tumefactive lesions at relapse (48; 02). Their median time to the second relapse was 4.8 years, an interval longer than reported for prototypic multiple sclerosis. The remaining one third of patients had a monophasic illness at last follow-up. These findings contrast with an earlier shorter duration study, with less than 5 years of follow-up for most patients, suggesting that patients with biopsy-proven tumefactive demyelinating lesions uniformly have a monophasic disease course (38). Another study, also with less than 5 years of follow-up for most patients, found that overall, two thirds of patients had a monophasic course within this time frame, with 50% of those with a ring-enhancing lesion on initial presentation relapsing, though Lucchinetti did not find a similar association. The presence of concomitant typical multiple sclerosis-appearing lesions also increased the probability of relapse (41.3% vs 9.6%, p< 0.005) independent of the imaging characteristics of the initial tumefactive lesions (91). Based on Lucchinetti’s finding that the average time to relapse after a tumefactive demyelinating lesion is 4.8 years, it is likely that an overall higher relapse rate would be detected with follow-up beyond 5 years. In infiltrative lesions, ring enhancement, multiple lesions, and infratentorial involvement were independent risk factors for relapse (44). Of this cohort, 48.3% had a definite etiology, most commonly multiple sclerosis, followed by MOG-associated disease, Balo concentric sclerosis, neuromyelitis optica spectrum disorders, and acute disseminated encephalomyelitis.
The prognosis of a cohort of 39 patients in India with tumefactive demyelinating lesions differed markedly from Lucchinetti’s, demonstrating a median time to relapse of 4 months, with the majority of patients having tumefactive lesions at relapse (58). Importantly, in an Indian cohort the incidence of multiple sclerosis is lower than in the United States and the incidence of ADEM is higher, and the cohort included children, who have a higher incidence of ADEM. In contrast, prognosis was favorable in a Thai cohort of 26 of 1102 CNS demyelinating cases in a multiple sclerosis and related disorders registry from two tertiary centers. Many presented with a monophasic condition, with 23.1% experiencing a subsequent relapse with a median time to next attack of 5 months (61). EDSS median was 4.3 at diagnosis and improved to 3.0 at the median follow up time of 48 months (range 6 to 300).
The discrepancies between findings in these various studies highlight the challenges of studying tumefactive demyelinating lesions, which are rare, may require long-term follow-up to detect relapses, and are caused by a heterogeneous group of diseases. Clinical features may offer insight into prognosis in a review of 35 patient. Clinical variables including aphasia or apraxia at onset was associated with disability within the first 3 months of greater than EDSS of 4. Factors associated with higher disability 2 years from onset included subacute-chronic onset, age greater than 40, and brainstem symptoms (72).
Prognosis and complications
The prognosis for patients with tumefactive demyelinating lesions is impacted primarily by the underlying CNS idiopathic inflammatory demyelinating disease, the location and size of the tumefactive lesions, the extent of mass effect, and the response to initial treatment. In general, long-term prognosis for tumefactive demyelinating lesions is favorable if recognized early and treated appropriately. Prognosis depends on whether the patient has a prior diagnosis of multiple sclerosis or is presenting with tumefactive demyelinating lesions as their first clinical event. Reportedly, 6% to 70% of patients presenting with a tumefactive demyelinating lesion as the first clinical event will develop a clinically definite multiple sclerosis (28). Despite this broad range, it is generally accepted that about two thirds of patients will follow a relapsing-remitting course and about one third will have no further clinical attacks (01). A small subset of patients presenting with tumefactive demyelinating lesions may relapse in a strictly tumefactive fashion. As noted above, the presence of ring enhancement on MRI and other typical multiple sclerosis-appearing lesions at presentation are associated with a higher incidence of relapse (91). Most studies agree that tumefactive demyelinating lesions do not typically evolve into a more active subtype of multiple sclerosis and recovery from tumefactive lesions is, in general, favorable (48; 02; 91; 11). Long-term disability associated with tumefactive demyelinating lesions was similar to a population-based multiple sclerosis cohort matched for disease duration (48). Index lesion size, location, and presence of mass effect or edema are not predictive of conversion to multiple sclerosis (48). However, very large initial lesion size (greater than 35 mm), mass effect, perilesional edema on MRI, and age greater than 30 years at initial presentation predicts a more aggressive disease course (66). Isolated intramedullary tumefactive lesions carry a worse prognosis, with only one of 14 patients in a mixed pediatric and adult cohort achieving full recovery (64).
Clinical vignette
A 23-year-old woman initially presented at 12 years of age with new-onset progressive left hemiparesis. The symptoms started in the left hand, then progressed to involve the left face and left lower extremity over a period of 1 week. Brain MRI revealed a large open-ring, gadolinium-enhancing lesion involving the right frontal lobe.
She underwent a craniotomy, and brain biopsy confirmed inflammatory demyelinating disease. She was treated with intravenous corticosteroids and completely recovered over a period of 5 weeks. At the age of 18 years, she had new-onset difficulty in language comprehension that progressed over 3 days. Brain MRI showed a new, large ring-enhancing lesion involving the left frontal lobe.
She was treated with intravenous corticosteroids and again had complete recovery over 4 to 5 weeks. At the age of 22 years, she developed severe early morning headaches. Brain MRI showed a new large, ring-enhancing lesion involving the right frontal lobe.
She was treated with intravenous corticosteroids and had a rapid clinical improvement. At the age of 23 years, she had ascending sensory loss to the umbilicus associated with urinary urgency. She was treated with intravenous steroids and completely recovered 11 days later. She was started on multiple sclerosis disease-modifying therapy with interferon beta1a weekly intramuscular injections for relapsing-remitting multiple sclerosis. Her EDSS score was 1.0 at last follow-up, 13 years after disease onset.
Biological basis
Etiology and pathogenesis
Pathology and pathogenesis differ depending on the type of CNS idiopathic inflammatory demyelinating disease.
Tumefactive demyelinating lesions.
Pathology. Tumefactive demyelination typically features classic characteristics of active inflammatory demyelinating disease including focal demyelination, variable inflammation, gliosis, and relative axonal sparing.
Up to 31% of diagnostic biopsies from patients with demyelinating lesions are misinterpreted. The most common misdiagnoses include glioma and infarction. Pathological features that cause difficulty in interpretation include hypercellularity, presence of necrosis and cystic changes, and the presence of reactive astrocytes with bizarre appearance, multiple nuclei, and mitotic figures, referred to as Creutzfeldt cells (94; 03; 20; 01). Zagzag and colleagues noted that the presence of foamy macrophages is an important feature suggestive of a demyelinating etiology. Once this is suspected, staining for myelin and axons can confirm the diagnosis (94). Sampling may also contribute to misinterpretation of demyelinating biopsies. Samples from the lesion edge may be misinterpreted as glioma; whereas samples from the lesion center may resemble infarct due to overabundance of macrophages (03; 01).
Pathogenesis. The immunopathogenesis of tumefactive demyelinating lesions remains uncertain. Early case reports suggested an association between tumefactive demyelinating lesions and vaccinations, leading to the hypothesis that these lesions represent an intermediate phenotype between multiple sclerosis and acute disseminated encephalomyelitis. However, this association was not found in subsequent studies (38; 48; 02; 28). It has been argued that as these lesions can develop in patients who typically go on to develop classic multiple sclerosis, this suggests that the lesions are part of the heterogenous spectrum of multiple sclerosis and not a transitional phenotype between acute disseminated encephalomyelitis and multiple sclerosis (38), recurrent acute disseminated encephalomyelitis (10), or a tumefactive multiple sclerosis variant (69).
The association of various immunosuppressants and occurrence of cases of tumefactive demyelinating lesions in association with HIV and acquired lymphopenia suggests a possible relationship between an adaptive cell-mediated immune defect and tumefactive demyelinating lesion pathogenesis rather than limiting the etiology to multiple sclerosis alone (42).
Marburg acute multiple sclerosis.
Pathology. Lesions may be disseminated throughout the brain and spinal cord, ranging in size from small to large confluent plaques. In some cases, there is diffuse demyelination throughout the brain and spinal cord. Microscopically, lesions are more destructive than typical multiple sclerosis lesions and characterized by significant macrophage infiltration, acute axonal injury, necrosis, and cavitation. Despite the degree of tissue destruction, variable remyelination is also evident.
Pathogenesis. The etiology of Marburg variant of multiple sclerosis is unclear. Myelin basic protein in patients with Marburg acute multiple sclerosis was found to have 18 citrullinyl residues compared with six in patients with chronic multiple sclerosis. The number of citrullinyl residues is thought to result in structural instability of myelin, causing severe demyelination as is seen in these patients (07). In a case report of a serial biopsy from a patient with Marburg acute multiple sclerosis, the initial biopsy (done on day 33) showed marked inflammation in the absence of demyelination, which became evident by the subsequent biopsy (day 109 of disease) (09). These findings are consistent with inflammation preceding demyelination.
Balo concentric sclerosis.
Pathology. Patients with Balo concentric sclerosis may have one or more lesions in the cerebral white matter, often sparing the cortical U fibers. Less common sites of demyelination associated with Balo concentric sclerosis include the basal ganglia, pons, cerebellum, and, rarely, the spinal cord and optic nerves. The pathological hallmark consists of concentric demyelination and oligodendrocyte loss characterized by alternating bands of demyelination with normal myelination or partial demyelination giving the appearance of onion bulbs. Lesions exhibit pattern III demyelination, characterized by distal oligodendrocyte dystrophy, composed of T lymphocytes and microglia and an absence of immunoglobulin and completement (36).
Pathogenesis. This pathological pattern of demyelination and tissue injury resembles a pattern seen in tissue ischemia. Similar to acute ischemia, a preferential loss of myelin-associated glycoprotein and oligodendrocyte apoptosis is seen in a subset of multiple sclerosis lesions. Because myelin-associated glycoprotein is localized at the distal inner glial loop, its early loss is interpreted as evidence of a dying-back gliopathy where the oligodendrocyte is unable to support the distal axon.
Different cellular responses to injury are found in the different rings of Balo concentric sclerosis lesions and display similarities to cellular mechanisms observed in hypoxia. In active areas of demyelination, macrophages, and microglia express nitric oxide synthase, indicating an attempt, although unsuccessful, to mitigate damage. In areas with rings of preserved myelin, oligodendrocytes express protective proteins involved in tissue preconditioning (eg, hypoxia-inducible factor 1alpha and heat shock protein 70). Astrocytes and macrophages in the same location also express these proteins, though to a lesser extent. This cellular rim is more resistant to further damage and forms the layer of preserved myelin in the lesion. This overexpression of tissue preconditioning molecules near the layer of active demyelination supports a role for histotoxic hypoxia in mediating the concentric pathology of demyelination (78). Studies have also found decreased levels of aquaporin 4 and connexins, highlighting the role of astrocyte dysfunction in Balo concentric sclerosis (46).
Epidemiology
The incidence of tumefactive demyelinating lesions is low, and precise estimates vary. A 2021 review of patients with tumefactive demyelination in Olmsted County, Minnesota found that out of 792 multiple sclerosis cases, 15 (1.9%) had tumefactive multiple sclerosis (23). It was the first clinical multiple sclerosis attack in half of the patients. The adjusted overall annual incidence rate was 0.57 out of 100,000.
A number of authors have tried to estimate the prevalence of tumefactive demyelinating lesions based on reviews of brain biopsies. Sugita and colleagues reviewed brain biopsies from 1231 cases coded as brain tumor or “unclassified” and found demyelination in three patients (0.24%) (79). Hunter and colleagues reported five of 1220 brain biopsies done over a 5-year period were consistent with inflammatory demyelinating disease (31). Two of the five biopsies were from the same patient. Annesley-Williams reported 0.09% of 15,394 retrospectively reviewed brain mass biopsy and autopsy specimens over a 22-year period demonstrated evidence of acute demyelination. Two of their patients had a prior history of multiple sclerosis (03).
Tumefactive demyelinating lesions typically present in the third decade (48; 02; 91) although Schilder disease and ADEM typically occur in children. There is some variability in age of presentation. Case reports describe a 13-month-old child (49) and an 87-year-old woman with pathologically confirmed tumefactive CNS demyelination (83). In the biopsy cohort of Lucchinetti and colleagues, 4% were younger than 18 years and 4% older than 65 years. A predilection for women may be present, although findings from studies differ. The ratio of women to men in Lucchinetti’s cohort was 1.2:1, suggesting an almost equal ratio. However, selection bias may have played a role in this biopsy-based cohort if clinicians are less likely to suspect inflammatory demyelination in men and, therefore, are more likely to biopsy. Two studies with patients enrolled based on radiographic findings of tumefactive demyelinating lesions found 62% to 68% of patients were women (02; 91).
Differential diagnosis
Making the diagnosis of tumefactive CNS idiopathic inflammatory demyelinating disease can be challenging. In addition to mimicking other diseases, such as brain tumors, tumefactive demyelinating lesions can be seen in other conditions (see Table 1). A detailed history and examination are essential to determine if there is evidence of previous demyelinating relapses. If CNS idiopathic inflammatory demyelinating disease is suspected, empiric therapy with intravenous steroids can be initiated. Tumefactive demyelinating lesions can look radiographically identical to high-grade gliomas on initial imaging; however, tumefactive demyelinating lesions will regress with serial imaging and generally respond clinically to high-dose steroids whereas high-grade gliomas will grow over time and not respond substantially to steroids (45). However, if CNS idiopathic inflammatory demyelinating disease is considered unlikely, steroids should be delayed to avoid obscuring the diagnosis, particularly of CNS lymphoma (57). Both tumefactive demyelinating disease and CNS lymphoma often demonstrate a rapid radiographic response to steroids, making diagnosis in the absence of biopsy challenging. Additional important considerations are that tumefactive demyelination may be the only finding on biopsy in patients with CNS lymphoma not previously treated with steroids (93) and that patients with known multiple sclerosis can develop brain tumors (12). Onset age of patients with tumefactive demyelinating lesions is younger than in CNS lymphoma, with an age of 37 +/- 14 years in tumefactive demyelinating lesions compared to 58 +/- years in primary CNS lymphoma (80). Patients with tumefactive demyelinating lesions are also more likely to be female and younger than in those with high grade glioma and CNS lymphoma (16). Presentation also differs, with patients with tumefactive demyelinating lesions more likely to have sensorimotor deficits and ataxia, whereas with high grade glioma and CNS lymphoma, headaches, and encephalopathy are more frequent.
Creutzfeldt-Peters cells and reactive astrocytes with fragmented nuclear inclusions on biopsy correlated with tumefactive demyelinating lesions. Pathological immune features, including type of demyelination, infiltrating cell type distribution, specific astrocyte pathology, and complement deposition, can be helpful in differentiating inflammatory etiology between multiple sclerosis, MOG-associated disease, or neuromyelitis optica spectrum disorder secondary to AQP4 (89).
Clinical and radiographic follow up are key, and repeat biopsy should be considered in cases where the diagnosis remains unclear. The differential diagnosis of tumefactive demyelinating lesions is wide and should be tailored to the clinical and radiological features. Table 1 summarizes the differential diagnosis of CNS idiopathic inflammatory demyelinating disease.
It is important to recognize that patients with multiple sclerosis may also develop neoplasms. A review of gliomas in patients with multiple sclerosis found that 30% of gliomas associated with multiple sclerosis were multicentric or diffusely infiltrative as compared to 2.5% to 5% of gliomas not associated with multiple sclerosis, suggesting a causal relationship to the multifocal disease of multiple sclerosis (73). Case reports vary as to whether the neoplastic process was adjacent to or infiltrated the multiple sclerosis lesions. Shuangshoti and colleagues hypothesized that neoplastic cells may originate from reactive astrocytes in inflammatory lesions (77). In patients with multiple sclerosis and oligodendrogliomas, a causal relationship can be hypothesized, with damage to oligodendrocytes causing oligodendrocyte proliferation in an effort to remyelinate axons, making the oligodendrocytes susceptible to malignant transformation (73). Based on the existing data, it is difficult to draw conclusions about whether there is a true association between multiple sclerosis and CNS neoplasia. However, the potential for concurrence should raise suspicion of an alternative diagnosis in a multiple sclerosis patient developing a new atypical mass lesion. Therefore, there should be careful clinical and radiographic follow-up of patients with multiple sclerosis presenting with new mass lesions.
Table 1. Differential Diagnosis of CNS Idiopathic Inflammatory Demyelinating Disease
|
Neoplastic |
Primary: glioma, gliomatosis cerebri, primary CNS lymphoma, intravascular lymphoma. |
|
Paraneoplastic |
Brainstem encephalitis |
|
Inflammatory |
Multiple sclerosis and variants |
|
Infectious |
Tuberculosis |
|
Vascular |
Neurosyphilis |
|
Toxic |
Drugs: methotrexate, 5FU, tacrolimus, TNF-alpha inhibitors, fingolimod, natalizumab, alemtuzumab |
|
Metabolic |
Mitochondrial cytopathy |
|
Radiation-induced | |
|
Other |
Reversible posterior leukoencephalopathy |
Diagnostic workup
Diagnostic work-up should be focused on the specific clinical scenario, with careful attention to the symptoms, signs, and setting. In a patient known to have multiple sclerosis, the diagnosis is more obvious. The workup of tumefactive demyelination is associated with higher cost and more adverse events than evaluation of conventional multiple sclerosis. One review of 32 patients with tumefactive demyelination and 32 with conventional multiple sclerosis noted that most of this financial burden and morbidity was related to biopsy, which is often necessary to rule out malignancy (76). Table 2 shows a list of possible diagnostic studies that can be considered in a patient suspected of having tumefactive demyelination.
Table 2. Diagnostic Work-up For a Patient with Possible Tumefactive Demyelination
|
Clinical or paraclinical evidence for demyelinating disease | |
|
• Careful history and clinical examination for evidence of prior neurologic episodes | |
|
Exclusion of alternative diagnoses (selection of tests will depend on the clinical presentation) | |
|
Laboratory studies (selected studies) | |
|
• ESR, ANCA | |
|
Additional CSF studies | |
|
• Pyruvate, lactate | |
|
Additional studies | |
|
• Echocardiography | |
Magnetic resonance imaging (MRI). Tumefactive demyelinating lesions tend to be well-circumscribed and typically involve white matter; however, gray matter lesions may also occur. Most patients have multifocal lesions; however, typically there is a large dominant lesion (18; 48). The large lesion is often supratentorial and usually involves the frontal or parietal lobes; however, periventricular, juxtacortical, subcortical, or corpus callosal lesions may also occur. Lesions involving the corpus callosum may have a butterfly configuration. This was observed in 12% of lesions in Lucchinetti’s cohort (48). In addition, 45% of lesions were associated with mass effect and two thirds were associated with edema, though the degree of mass effect and edema tend to be less than is observed with tumors. Almost all lesions enhance with gadolinium with a variety of enhancement patterns. The most common patterns of enhancement are irregular rim and ring enhancement (either open- or closed-ring); however, other patterns are also observed (41; 48).
Ring-like lesions are associated with a higher rate of relapse (91). A pattern of open-ring enhancement with the ring open to the gray matter side can be an important clue to the presence of tumefactive demyelination (53). A radiographic-pathologic correlation study found that MRI patterns of open-ring and irregular rim enhancement were associated with infiltration of macrophages and angiogenesis, whereas a pattern of inhomogeneous enhancement was associated with perivascular lymphocytic cuffing (41). Lesions with an inflammatory core can show increased intensity on diffusion-weighted sequences with correlated low signal of apparent diffusion coefficient sequences. Diffusion restriction may also be seen peripherally in the lesion. These correlations are similar to prior studies in multiple sclerosis without tumefactive demyelination. T2-weighted MRI allows calculation of cerebral blood volume to determine vascularity of lesions. Tumefactive demyelinating lesions exhibit normal vasculature, whereas tumors provoke neovascularization and angiogenesis. A ratio of relative cerebral blood volume to contralateral normal white matter yielded a statistically significant difference in intracranial neoplasms versus demyelinating lesions (15). Follow-up MRI can be helpful in distinguishing etiology for tumefactive demyelinating lesions, with resolution more common in MOG-associated disease than multiple sclerosis or neuromyelitis optica spectrum disorders associated with AQP-4 (13).
Magnetic resonance spectroscopy. The role of magnetic resonance spectroscopy in the diagnosis of tumefactive demyelination is not clear and studies have had conflicting results. There are differences between pseudotumoral demyelinating lesions and solid brain masses in several metabolites, including myo-inositol, NAA, glutamine, and choline (50). A serial study of a demyelinating lesion demonstrated an initial peak in lipid and lactate that normalized after 4 weeks. Reduction in NAA (neuronal marker) correlates with the degree of axonal damage in the lesion (21). Gliomas and acute demyelinating plaques show a similar spectral pattern of increased Cho/Cr and reduction in NAA/Cr (43). A larger study was able to differentiate tumefactive demyelinating lesions from high-grade gliomas by means of the mean Cho/NAA ratio, with encouraging sensitivity and specificity. However, this study, like the others, was small, with only four patients with tumefactive demyelinating lesions. Although this technique shows promise for minimizing costs and morbidity, it is not yet as effective as tissue biopsy in securing an accurate diagnosis. However, Cho/NAA as an adjunct to conventional MRI does appear to improve diagnostic ability (47).
Computed tomography. CT may serve as a helpful adjunct to MRI in distinguishing tumefactive demyelinating lesions from tumors. Areas of MRI enhancement are hypodense on unenhanced CT scan significantly more often with tumefactive demyelination (93%) than with tumors (4%), including CNS lymphoma (39). Patients with primary CNS lymphoma are more likely to have hyperdense lesions (80).
Positron emission tomography. A small study of five patients using fluoro-deoxyglucose PET showed a marginal increase in metabolism in tumefactive lesions compared to the typical marked increase in metabolism seen in tumors, making PET potentially informative in distinguishing these lesions from neoplasms (82).
Another PET modality, using the translocator protein (TSPO) radiotracer, was used to compare tumefactive and Balos concentric sclerosis lesions to relapsing-remitting multiple sclerosis lesions. TSPO detects activated microglia and CNS macrophages and is a promising approach for assessing inflammation. Tumefactive multiple sclerosis shows diffuse TSPO tracer uptake, even beyond the region of contrast enhancement on MRI. In Balos concentric sclerosis, PET shows concentric circular areas of inflammatory cell activation that correlate with enhancement on MRI (90).
CSF studies. CSF studies are often avoided in patients with large tumefactive lesions associated with mass effect due to concerns of raised intracranial pressure. As such, there are limited large retrospective reviews on this topic. In the study of Lucchinetti and colleagues, 62 of the patients had CSF studies prior to brain biopsy. In 33%, oligoclonal bands were present, and 35% had an elevated IgG synthesis rate (48). This study was retrospective, and CSF analyses were done in different laboratories under different conditions; therefore, firm conclusions are difficult to draw. However, it is possible that patients with tumefactive demyelinating lesions have a lower frequency of oligoclonal bands and elevated IgG synthesis rate compared to prototypic multiple sclerosis. This may also be a result of selection bias in a biopsied cohort in that patients with positive oligoclonal bands were perhaps less likely to undergo brain biopsy.
A retrospective review of the CSF findings in patients diagnosed with Balos concentric sclerosis found that oligoclonal bands were only present in 31% to 37% and suggests that the CSF profiles of these patients were more similar to neuromyelitis optica or myelin oligodendrocyte glycoprotein-associated encephalomyelitis than to multiple sclerosis (34). A similar retrospective analysis by the same group targeting those diagnosed with Schilder disease found similar findings. Most of these cases were negative for oligoclonal bands (74%). Additionally, Epstein-Barr virus antibodies were absent in 5 cases of Schilder disease, but are present in nearly all patients with multiple sclerosis (35). In addition to a decrease in oligoclonal bands, there is a higher median white cell count in MOG-associated disease and neuromyelitis optica spectrum disorders compared to multiple sclerosis (13).
Brain biopsy. Brain biopsy has an important role in diagnosis of tumefactive demyelination. It is indicated in situations when the diagnostic work-up is inconclusive and the patient is either severely ill or rapidly declining despite therapy and there is urgent need for a definitive diagnosis.
Management
There are no controlled trials of acute management of patients with tumefactive demyelinating lesions as it is a rare condition. High-dose intravenous corticosteroids (methylprednisolone 1 gram intravenous for 5 days) are typically the first-line management for tumefactive relapses. A subgroup of patients with fulminant attacks of CNS idiopathic inflammatory demyelinating disease refractory to steroid therapy may respond to plasma exchange (32; 92; 51). For patients who continue to worsen or have relapses of disabling tumefactive lesions, escalation to rituximab or cyclophosphamide may be appropriate (22; 74; 75). A retrospective review found neurologic improvement with cyclophosphamide treatment in 10 out of 12 patients with tumefactive multiple sclerosis who had been refractory to corticosteroids and plasma exchange treated with cyclophosphamide (24). Aggressive, supportive management in the acute phase, including measures to reduce raised intracranial pressure, is crucial because the anticipated long-term outcome of many of these patients is good. Decompressive surgery may be considered in patients with large demyelinating lesions causing impending herniation (70). For those patients diagnosed to have definite multiple sclerosis, treatment using currently approved multiple sclerosis immunomodulatory agents should be initiated.
Outcomes
It is generally accepted that about two thirds of patients that present with tumefactive demyelinating lesions will follow a relapsing-remitting course and about one third will have no further clinical attacks (01). In those who do have further attacks, the median time for a second clinical attack is close to 5 years (48), which is longer than the 1.9 to 3 years for a typical multiple sclerosis demyelinating event (19). A potential explanation is the more aggressive immunomodulatory therapy provided for many patients with tumefactive demyelinating lesions. In patients with a prior diagnosis of multiple sclerosis, tumefactive demyelinating lesions are associated with a higher risk of clinical relapse and development of new T2 lesions but are not predictive of faster disability progression (86).
Special considerations
Pregnancy
Although tumefactive demyelinating lesions are not thought to be particularly associated with pregnancy, there is one case report of initial presentation of tumefactive multiple sclerosis during pregnancy (62). After poor response to high-dose intravenous steroids and plasma exchange, this patient had an elective termination and had clinical improvement with initiation of multiple sclerosis disease-modifying therapy and rehabilitation.
Media
References
- 01
- Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord 2017;14:72-9. PMID 28619436
- 02
- Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 2012;18(10):1448-53. PMID 22419670
- 03
- Annesley-Williams D, Farrell MA, Staunton H, Brett FM. Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropath Exp Neurol 2000;59:477-89. PMID 10850860
- 04
- Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016;263(1):25-9. PMID 26477020
- 05
- Balo J. Encephalitis periaxialis concentrica. Arch Neurol 1928;19:242-63.
- 06
- Barton J, Hardy TA, Riminton S, et al. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology 2017;88(10):1004-6. PMID 28179462
- 07
- Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G. Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun 1999;1:48-51. PMID 10329477
- 08
- Beume LA, Dersch R, Fuhrer H, Stich O, Rauer S, Niesen WD. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab. J Clin Neurosci 2015;22(2):400-1. PMID 25150761
- 09
- Bitsch A, Wegener C, da Costa C, et al. Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler 1999;5:138-46. PMID 10408713
- 10
- Brinar VV. Non-MS recurrent demyelinating diseases. Clin Neurol Neurosurg 2004;106:197-210. PMID 15177769
- 11
- Brod SA, Lindsey JW, Nelson F. Tumefactive demyelination: clinical outcomes, lesion evolution and treatments. Mult Scler J Exp Transl Clin 2019;5(2):2055217319855755. PMID 31245023
- 12
- Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M. Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro Endocrinol Lett 2008;29(6):867-70. PMID 19112415
- 13
- Cacciaguerra L, Morris P, Tobin WO, et al. Tumefactive demyelination in MOG Ab-associated disease, multiple sclerosis, and AQP-4-IgG-positive neuromyelitis optica spectrum disorder. Neurology 2023;10.1212/WNL.0000000000206820. PMID 36690455
- 14
- Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012;79(19):2004-5. PMID 23035063
- 15
- Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001;22(6):1109-16. PMID 11415906
- 16
- Chew SH, Achmad Sankala HB, Chew E, et al. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study. Mult Scler Relat Disord 2023;79:104992. PMID 37717306
- 17
- Chitnis T, Hollmann TJ. CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia? Neurology 2012;78:221-3. PMID 22218279
- 18
- Comi G. Multiple sclerosis: pseudotumoral forms. Neurol Sci 2004;25(Suppl 4):S374-9. PMID 15727238
- 19
- Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15(3):257-66. PMID 12045722
- 20
- Di Patre PL, Castillo V, Delavelle J, Vuillemoz S, Picard F, Landis T. "Tumor-mimicking" multiple sclerosis. Clin Neuropath 2003;22:235-9. PMID 14531548
- 21
- Enzinger C, Strasser-Fuchs S, Ropele S, Kapeller P, Kleinert R, Fazekas F. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging. Mult Scler 2005;11:135-9. PMID 15794384
- 22
- Fan X, Mahta A, De Jager PL, Kesari S. Rituximab for tumefactive inflammatory demyelination: a case report. Clin Neurol Neurosurg 2012;114(10):1326-8. PMID 22475882
- 23
- Fereidan-Esfahani M, Decker PA, Eckel Passow JE, Lucchinetti CF, Flanagan EP, Tobin WO. Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. Eur J Neurol 2021;29(3):782-9. PMID 34773343
- 24
- Fereidan-Esfahani M, Tobin WO. Cyclophosphamide in treatment of tumefactive multiple sclerosis. Mult Scler Relat Disord 2021;47:102627. PMID 33246262
- 25
- Ferreira D, Castro S, Nadais G, Dias Costa JM, Fonseca JM. Demyelinating lesions with features of Balo’s concentric sclerosis in a patient with active hepatitis C and human herpes virus 6 infection. Eur J Neurol 2011;18:e6-7. PMID 20849439
- 26
- Fragoso YD, Adoni T, Gomes S, et al. Severe exacerbation of multiple sclerosis following withdrawal of fingolimod. Clin Dug Investig 2019;39(9):909-13. PMID 31152369
- 27
- Graber JJ, Kister I, Geyer H, Khaund M, Herbert J. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 2009;66:274-5. PMID 19204169
- 28
- Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 2013;84(9):1047-53.** PMID 23334629
- 29
- Hardy TA, Miller DH. Balo’s concentric sclerosis. Lancet Neurol 2014;13:740-46. PMID 24943346
- 30
- Hellmann MA, Lev N, Lotan I, et al. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci 2014;344(1-2):193-7. PMID 25001515
- 31
- Hunter S, Ballinger W, Rubin J. Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med 1987;111:464–8. PMID 3566474
- 32
- Jacquerye P, Ossemann M, Laloux P, Dive A, De Coene B. Acute fulminant multiple sclerosis and plasma exchange. Eur Neurol 1999;41:174-5. PMID 10202254
- 33
- Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18(11):1650-2. PMID 23100527
- 34
- Jarius S, Würthwein C, Behrens JR, et al. Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. J Neuroinflammation 2018;15(1):22. PMID 29347989
- 35
- Jarius S, Haas J, Paul F, Wildemann B. Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. J Neuroinflammation 2019;16(1):51. PMID 30819213
- 36
- Jolliffe EA, Guo Y, Hardy TA, et al. Clinical and radiologic features, pathology, and treatment of Baló concentric sclerosis. Neurology 2021;97(4):e414-22. PMID 34011576
- 37
- Karaarslan E, Altintas A, Senol U, et al. Balo’s concentric sclerosis: clinical and radiologic features of five cases. Am J Neuroradiol 2001;22:1362-7. PMID 11498428
- 38
- Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis. A study of 31 patients. Ann Neurol 1993;33:18-27. PMID 8494332
- 39
- Kim DS, Na DG, Kim KH, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 2009;251:467-75. PMID 19261924
- 40
- Kishimoto R, Yabe I, Niino M, et al. Balo's concentric sclerosis-like lesion in the brainstem of a multiple sclerosis patient. J Neurol 2008;255:760-1. PMID 18293025
- 41
- Kobayashi M, Shimizu Y, Shibata N, Uchiyama S. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology. J Neurol 2014;261:1902-10. PMID 25034274
- 42
- Koudriavtseva T, Lorenzano S. A possible role of impaired cell-mediated immunity in the pathogenesis of tumefactive demyelinating lesions. Mult Scler Relat Disord 2017;18:184-5. PMID 29141807
- 43
- Law M, Meltzer DE, Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 2002;44:986-9. PMID 12483443
- 44
- Li X, Miao X, Wang Y, et al. Central nervous system tumefactive demyelinating lesions: risk factors of relapse and follow-up observations. Front Immunol 2022;13:1052678. PMID 36532021
- 45
- Lin M, Reid P, Bakhsheshian J. Tumefactive multiple sclerosis masquerading as high grade glioma. World Neurosurg 2018;112:37-8. PMID 29331745
- 46
- Linnoila J, Chitnis T. Balo concentric sclerosis in children: a case series. J Child Neurol 2014;29(5):603-7. PMID 24423690
- 47
- Lu SS, Kim SJ, Kim HS, et al. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2014;35(2):270-7. PMID 23928144
- 48
- Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008;131:1759-75.** PMID 18535080
- 49
- Maeda Y, Kitamoto I, Kurokawa T, Ueda K, Hasuo K, Fujioka K. Infantile multiple sclerosis with extensive white matter lesions. Ped Neurol 1989;5:317-9. PMID 2803391
- 50
- Majos C, Aguilera C, Alonso J, et al. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009;30(3):544-51. PMID 19095788
- 51
- Mao-Draayer Y, Braff S, Pendlebury W, Panitch H. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 2002;59:1074-7. PMID 12370466
- 52
- Markiewicz D, Adamczewska-Goncerzewicz Z, et al. A case of primary form of progressive multifocal leukoencephalopathy with concentric demyelination of Balo type. Neuropatol Pol 1977;15:491-500. PMID 414153
- 53
- Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 2000;54:1427-33. PMID 10751251
- 54
- McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7. PMID 11456302
- 55
- Moghadasi AN. Tumefactive demyelinating lesions in a patient with multiple sclerosis developed two days after the injection of rituximab. Acta Neurol Taiwan 2020;29(4):124-7. PMID 34018172
- 56
- Moreira Ferreira VF, Meredith D, Stankiewicz J. Tumefactive demyelination in a patient with relapsing-remitting MS on Ocrelizumab. Neurol Neuroimmunol Neuroinflamm 2019;6(5). PMID 31454764
- 57
- Naeem SB, Niazi F, Baig A, Sadiq H, Sattar M. Primary CNS lymphoma vs. tumefactive multiple sclerosis: a diagnostic challenge. J Coll Physicians Surg Pak 2018;28(1):66-8. PMID 29290197
- 58
- Nagappa M, Taly AB, Sinha S, et al. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients. Acta Neurol Scand 2013;128(1):39-47. PMID 23277913
- 59
- Ng SH, Ko SF, Cheung YC, Wong HF, Wan YL. MRI features of Baló's concentric sclerosis. Brit J Radiol 1999;72:400-3. PMID 10474505
- 60
- Nozaki K, Abou-Fayssal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report. J Neurol Sci 2010;296(1-2):121-3. PMID 20579663
- 61
- Ongphichetmetha T, Aungsumart S, Siritho S, et al. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep 2024;14(1):1426. Erratum in: Sci Rep 2024;14(1):5332. PMID 38228919
- 62
- Pakneshan S, Bernitsas E. Fulminant tumefactive multiple sclerosis in pregnancy. BMJ Case Rep 2017;2017. PMID 28611164
- 63
- Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-5. PMID 3340277
- 64
- Pérez CA, Patnaik A, Oommen S, Redko A, Mathis SB. Tumefactive demyelinating lesions in children: a rare case of conus medullaris involvement and systematic review of the literature. J Child Neurol 2020;35(10):690-9. PMID 32552343
- 65
- Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 2013;81(19):1654-8. PMID 24097813
- 66
- Plowman RS, Varma H. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study. J Neurol Sci 2021;428:117591. PMID 34333380
- 67
- Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302. PMID 21387374
- 68
- Poser CM, Goutieres F, Carpentier MA, Aicardi J. Schilder's myelinoclastic diffuse sclerosis. [Erratum in: Pediatrics 1986 Jul;78(1):138]. Pediatrics 1986;77:107-12. PMID 3940347
- 69
- Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K. Acute demyelinating disease: classification and non-invasive diagnosis. Acta Neurol Scand 1992;86:579-85. PMID 1481644
- 70
- Ragel BT, Fassett DR, Baringer JR, Browd SR, Dailey AT. Decompressive hemicraniectomy for tumefactive demyelination with transtentorial herniation: observation. Surg Neurol 2006;65:582-3. PMID 16720180
- 71
- Sanchez P, Meca-Lallana V, Vivancos J. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases. Mult Scler Relat Disord 2018;25:95-8. PMID 30056362
- 72
- Saridas F, Mesut G, Ceylan CY, et al. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology. Mult Scler Relat Disord 2024;85:105537. PMID 38460252
- 73
- Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg 2006;108(3):259-65. PMID 16378678
- 74
- Sempere AP, Feliu-Rey E, Sanchez-Perez R, Nieto-Navarro J. Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J Neurol Neurosurg Psychiatry 2013;84(12):1338-9. PMID 23804236
- 75
- Siffrin V, Müller-Forell W, von Pein H, Zipp F. How to treat tumefactive demyelinating disease? Mult Scler 2014;20(5):631-3. PMID 24347182
- 76
- Silsby M, Sánchez P, Spies JM, et al. Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis. Mult Scler Relat Disord 2019;35:104-7. PMID 31362165
- 77
- Shuangshoti S, Hjardermaal GM, Ahmad Y, Arden JL, Herman MM. Concurrence of multiple sclerosis and intracranial glioma: report of a case and review of the literature. Clin Neuropath 2003;22:304-8. PMID 14672509
- 78
- Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005;128:979-87. PMID 15774507
- 79
- Sugita Y, Terasaki M, Shigemori M, Sakata K, Morimatsu M. Acute focal demyelinating disease simulating brain tumors: histopathologic guidelines for an accurate diagnosis. Neuropath 2001;21:25-31. PMID 11304039
- 80
- Sun C, Han J, Lin Y, et al. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma. Front Immunol 2022;13:986473. PMID 36059526
- 81
- Suzuki M, Kawasaki H, Masaki K, et al. An Autopsy Case of the Marburg Variant of Multiple Sclerosis (Acute Multiple Sclerosis). Intern Med 2013;52:1825-32. PMID 23955619
- 82
- Takenaka S, Shinoda J, Asano Y, et al. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET. Brain Tumor Pathol 2011;28:229-38. PMID 21442242
- 83
- Takeuchi T, Ogura M, Sato M, et al. Late-onset tumefactive multiple sclerosis. Rad Med 2008;26:549-52. PMID 19030964
- 84
- Talab R, Kundrata Z. Marburg variant multiple sclerosis - a case report. Neuro Endocrinol Lett 2011;32(4):415-20. PMID 21876497
- 85
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-73. PMID 29275977
- 86
- Totaro R, Di Carmine C, Spendiani A, et al. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis. Neuro Sci 2016;37(7):1113-7. PMID 27083895
- 87
- Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261(1):1-16. PMID 24272588
- 88
- Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg's variant multiple sclerosis. Neurol Sci 2010;31(6):807-11. PMID 20461429
- 89
- Vakrakou AG, Brinia ME, Svolaki I, Argyrakos T, Stefanis L, Kilidireas C. Immunopathology of tumefactive demyelinating lesions-from idiopathic to drug-related cases. Front Neurol 2022;13:868525. PMID 35418930
- 90
- Völk S, Unterrainer M, Albert NL, et al. TSPO PET with 18F-GE-180 to differentiate variants of multiple sclerosis: relapsing-remitting multiple sclerosis, tumefactive demyelination, and Baló's concentric sclerosis. Clin Nucl Med 2020;45(10):e447-8. PMID 32796248
- 91
- Wallner-Blazek M, Rovira A, Fillipp M, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 2013;260:2016-22. PMID 23620065
- 92
- Weinshenker BG. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis 1999;14:144-8. PMID 10540370
- 93
- Yamamoto J, Shimajiri S, Nakano Y, Nishizawa S. Primary central nervous system lymphoma with preceding spontaneous pseudotumoral demyelination in an immunocompetent adult patient: A case report and literature review. Oncol Lett 2014;7(6):1835-8. PMID 24932243
- 94
- Zagzag D, Miller DC, Kleinman GM, Abati A, Donnenfeld H, Budzilovich GN. Demyelinating disease versus tumor in surgical neuropathology: clues to a correct pathological diagnosis. Am J Surg Path 1993;17:537-45. PMID 8333553
- 95
- Zanotti C, Chiarini M, Serana F, et al. Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients. J Neuroimmunol 2011;240-241:147-50. PMID 22078237
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Michael A Lane MD
Dr. Lane of the Oregon Health and Science University and VA Portland Health Care System has no relevant financial relationships to disclose.
See Profile -
Chris W Hollen MD
Dr. Hollen of Oregon Health & Science University has no relevant financial relationships to disclose.
See Profile
Editor
-
Anthony T Reder MD
Dr. Reder of the University of Chicago received honorariums from Biogen Idec, Genentech, Genzyme, and TG Therapeutics for service on advisory boards and as a consultant as well as stock options from NKMax America for advisory work and an unrestricted lab research grant from BMS.
See Profile
Former Authors
- Meredith Frederick MD
- Michelle Cameron MD
Patient Profile
- Age range of presentation
-
- 1 month to 65+ years
- Sex preponderance
-
- female>male, >1:1
- Heredity
-
- heredity may be a factor
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Multiple sclerosis: G35.
- Neuromyelitis optica: G36.0
- Schilder disease: G37.0
- Balo concentric sclerosis: G37.5
- Demyelinating disease of central nervous system, unspecified: G37.9
- ICD-11
-
- Multiple sclerosis: 8A40
- Isolated demyelinating syndromes of the central nervous system: 8A41
- Neuromyelitis optica: 8A43
- Other specified multiple sclerosis: 8A40.Y
- Multiple sclerosis or other white matter disorders, unspecified: 8A4Z
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
General Neurology
Encephalitis lethargica
Dec. 28, 2024
-
Neuroimmunology
Autoantibodies: mechanism and testing
Dec. 20, 2024
-
Neuroimmunology
Natalizumab and PML in MS
Dec. 20, 2024
-
Neuroimmunology
Chronic fatigue syndrome
Dec. 12, 2024
-
Neuroimmunology
Immunoglobulin light chain amyloidosis: neurologic complications
Dec. 07, 2024
-
Neuroimmunology
Clinical trials in multiple sclerosis
Nov. 27, 2024
-
Neuroimmunology
Multiple sclerosis: treatment of its symptoms
Oct. 30, 2024